Toxicologic evaluation of streptozotocin (NSC 85998) in mice, dogs and monkeys.
Single intravenous doses of CDF1 mice, and single and five daily intravenous treatment schedules in beagle dogs and rhesus monkeys were used to evaluate the toxicity of Streptozotocin (SZN). The major target organs in the three species were liver, kidney, lymphoid tissue and pancreatic islet beta cells. Moderate bone marrow depression and gastrointestinal toxicity were observed in the large animal species after lethal doses. Monkeys were less sensitive than the dog to the hepatotoxic effects of SZN and clinical signs of liver dysfunction were more severe in dogs after multiple doses. Microscopic lesions in the renal proximal convoluted tubules were present in the three species; these lesions appeared to be irreversible for dogs. The toxic effect on the endocrine pancreas was manifest by hyperglycemia, glucosuria, islet atrophy and beta cell degranulation. Multiple dose regimens were less toxic than single doses in dogs and monkeys in terms of the total dose received.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004285:Dogs; D005260:Female; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008221:Lymphoid Tissue / Q000187:drug effects / Q000473:pathology; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D010179:Pancreas / Q000187:drug effects; D013045:Species Specificity; D013311:Streptozocin / Q000633:toxicity*
D013311:Streptozocin